Immunomedics Reports Updated Results With 90Y-Clivatuzumab Tetraxetan in Patients With Metastatic Pancreatic Cancer

Immunomedics Reports Updated Results With 90Y-Clivatuzumab Tetraxetan in
Patients With Metastatic Pancreatic Cancer

  -- Overall Survival of 7.9 Months in Patients Receiving Multiple Cycles of
              Treatment in Combination of Low-Dose Gemcitabine –

 -- Results Presented at Press Conference of American Association for Cancer
   Research (AACR) Special Conference on Pancreatic Cancer: Innovations in
                          Research and Treatment --

NEW ORLEANS, May 19, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU)
today announced that patients receiving multiple cycles of the investigational
pancreatic cancer therapeutic, clivatuzumab tetraxetan labeled with yttrium-90
(^90Y), in combination with low-dose gemcitabine, had increased survival

Vincent J. Picozzi Jr., M.D., Director of the Pancreas Center of Excellence at
the Virginia Mason Medical Center's Digestive Disease Institute, Seattle, WA,
presented the updated Phase Ib study at a press conference hosted by AACR at
its special conference on Pancreatic Cancer. This is one of only 3 studies
that have been selected by AACR to participate in the media outreach program.
The full poster presentation will occur on Tuesday, May 20, 2014 from
12:30-3:00 p.m. Central Time.

"We found that ^90Y-clivatuzumab tetraxetan, when used with low-dose
gemcitabine, is a safe, low-side effect therapy that can prolong survival for
at least some patients with metastatic pancreatic cancer, even when no
chemotherapy options exist," remarked Dr. Picozzi. "Our studies imply that
radiolabeled antibodies are safe to use in advanced pancreatic cancer, and
that it may be possible to attach other anticancer agents besides ^90Y to
clivatuzumab tetraxetan to fight pancreatic cancer," he added.

A total of 58 patients with pancreatic cancer who had received two or more
prior therapies were enrolled in this multicenter study. Twenty-nine patients
received the combination of ^90Y-labeled-clivatuzumab tetraxetan once-a-week
for 3 weeks and gemcitabine given weekly for 4 weeks (Arm A) while another
group of 29 patients were administered 4 doses of ^90Y-labeled-clivatuzumab
tetraxetan alone (Arm B). This treatment cycle was repeated every 4 weeks
until unacceptable toxicity, patient deterioration or patient withdrawal.
Twenty-three patients completed more than one cycle of treatment, with 12
patients in Arm A and 11 in Arm B.

Notwithstanding the late-stage setting with a difficult-to-treat cancer,
patients in Arm A had a median overall survival (OS) of 7.9 months, which was
statistically significant (p = 0.004) over the median OS of 3.4 months in
patients treated repeatedly with the radiolabeled antibody alone (Arm B).
Additionally, 2 patients in Arm A had a partial response and 2 patients are
still alive 13 and 15 months after the start of their combination treatment.

The only clinically significant side effect was reduction in blood counts,
especially platelets, which was transient and manageable.

"We have launched the Phase III PANCRIT-1 registration trial to confirm these
encouraging results," commented Cynthia L. Sullivan, President and Chief
Executive Officer of Immunomedics. "We plan to complete patient accrual by the
middle of 2015, with top-line results expected in the first half of 2016," Ms.
Sullivan added.


The PANCRIT-1 trial was designed to enroll approximately 440 patients with
metastatic pancreatic cancer who had received at least two prior therapies. A
majority of these patients will be recruited at clinical trial sites across
the U.S., with additional sites in Canada, Europe and Israel participating.
Eligible patients will be randomized 2 to 1 to the treatment arm of 3 doses of
^90Y-clivatuzumab tetraxetan plus 4 doses of gemcitabine at 200 mg/m^2 per
cycle or placebo plus 200 mg/m^2 gemcitabine. All patients will receive best
supportive care. Treatments are administered during the initial 4 weeks of
each 7-week cycle, and may be repeated up to a maximum of 6 cycles.

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing
monoclonal antibody-based products for the targeted treatment of cancer,
autoimmune disorders and other serious diseases. Immunomedics' advanced
proprietary technologies allow the Company to create humanized antibodies that
can be used either alone in unlabeled or "naked" form, or conjugated with
radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these
technologies, Immunomedics has built a pipeline of nine clinical-stage product
candidates. Immunomedics has an ongoing collaboration with UCB, S.A. (UCB),
who has worldwide rights in non-cancer indications to Immunomedics' Phase III
product candidate, epratuzumab. UCB expects Phase III data in systemic lupus
erythematosus (SLE) in the first quarter of 2015. Immunomedics is exploring
epratuzumab in oncology in collaboration with outside cancer study groups.
Immunomedics' most advanced wholly owned candidate is ^90Y-clivatuzumab
tetraxetan, which is in an ongoing Phase III registration trial in patients
with pancreatic cancer. Immunomedics' portfolio of wholly owned product
candidates also includes antibody-drug conjugates (ADCs) that are designed to
deliver a specific payload of a chemotherapeutic directly to the tumor while
reducing overall toxicity effects that typically occur when these
chemotherapeutic agents are dosed alone. Immunomedics' most advanced ADCs are
IMMU-132 and IMMU-130, which are in Phase I/II trials for a number of solid
tumors and metastatic colorectal cancer (mCRC), respectively. Immunomedics
also has a number of other product candidates that target solid tumors and
hematologic malignancies, as well as other diseases, in various stages of
clinical and pre-clinical development. These include bispecific antibodies
which have application as T-cell redirecting immunotherapies targeting cancers
and infectious diseases as well as next-generation therapies in cancer and
autoimmune disease. Immunomedics creates these bispecific antibodies using its
patented DOCK-AND-LOCK™ (DNL™) protein conjugation technology. The Company
believes that its portfolio of intellectual property, which includes
approximately 248 active patents in the United States and more than 400
foreign patents, protects its product candidates and technologies.
Immunomedics' strength in intellectual property has resulted in the top-4
ranking in the January 2014 Patent Board scorecard in the Biotechnology
industry. For additional information on the Company, please visit its website
at The information on its website does not, however,
form a part of this press release.

This release, in addition to historical information, may contain
forward-looking statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Such statements, including statements regarding clinical
trials (including the funding therefor, outcomes, timing or associated costs),
out-licensing arrangements (including the timing and amount of contingent
payments), forecasts of future operating results, potential collaborations,
and capital raising activities, involve significant risks and uncertainties
and actual results could differ materially from those expressed or implied
herein. Factors that could cause such differences include, but are not limited
to, new product development (including clinical trials outcome and regulatory
requirements/actions), our dependence on UCB for the further development of
epratuzumab for non-cancer indications, risks associated with the outcome of
pending litigation, competitive risks to marketed products and availability of
required financing and other sources of funds on acceptable terms, if at all,
as well as the risks discussed in the Company's filings with the Securities
and Exchange Commission. The Company is not under any obligation, and the
Company expressly disclaims any obligation, to update or alter any
forward-looking statements, whether as a result of new information, future
events or otherwise.

CONTACT: For More Information:
         Dr. Chau Cheng
         Senior Director, Investor Relations & Grant Management
         (973) 605-8200, extension 123
Press spacebar to pause and continue. Press esc to stop.